CHINA
China | Data exclusivity comes into effect
Protection of Drug Trial Data on 15 May 2026 with immediate effect, i.e. simultaneously with the Implementing Regulations of the Drug Administration Law (2026 Revisions). The enforcement of...
Protection of Drug Trial Data on 15 May 2026 with immediate effect, i.e. simultaneously with the Implementing Regulations...
Read More
GREATER CHINA
China | Punitive damages in intellectual property civil cases
Supreme People Court (SPC) 2026 Judicial Interpretation. The 2026 SPC Interpretation further refines and supplements the rules set out in the 2021 version and addresses practical issues arising in judicial practice over recent years, including determining of...
Supreme People Court (SPC) 2026 Judicial Interpretation. The 2026 SPC Interpretation further refines and supplements the rules set out in the 2021 version and addresses...
Read More
AUSTRALASIA
Extending Protection for Pharmaceuticals | Requirements in Australia, China and Singapore
Our teams across the Asia Pacific explore how pharmaceutical innovators can extend protection for their therapeutic products through patent term extensions (PTEs) and data exclusivity in Australia, China, and Singapore.  A comparison table is provided below which summarises key requirements and timing considerations for...
Our teams across the Asia Pacific explore how pharmaceutical innovators can extend protection for their therapeutic products through patent term extensions (PTEs) and data...
Read More
GREATER CHINA
Guide to protecting your Trade Secrets under China’s new Regulations
On 24 February 2026, China’s State Administration for Market Regulation (“SAMR”) issued the Regulations on the Protection of Trade Secrets (Announcement No. 126 of the State Administration for Market...
On 24 February 2026, China’s State Administration for Market Regulation (“SAMR”) issued the Regulations on the Protection of Trade...
Read More
CHINA
Market Exclusivity and Data Exclusivity included in Drug Administration Law revisions
Marking a milestone in China’s drug regulatory landscape, the 2026 Revisions of China’s Drug Administration Law introduce data exclusivity and market exclusivity into the regulatory framework, establishing a multi‑dimensional...
Marking a milestone in China’s drug regulatory landscape, the 2026 Revisions of China’s Drug Administration Law introduce data exclusivity...
Read More
GREATER CHINA
China | Amendments to Patent Examination Guidelines finalised
After six months of drafting and revisions, the China National Intellectual Property Administration (CNIPA) issued the finalised version of the Guidelines for Patent Examination on 13 November 2025. These revisions will...
After six months of drafting and revisions, the China National Intellectual Property Administration (CNIPA) issued the finalised version of...
Read More
GREATER CHINA
China | Draft changes to dual filing in China
With double patenting prohibited in China, many applicants have utilised a dual filing strategy to secure patent rights, but this may be set to change. As noted in our article...
With double patenting prohibited in China, many applicants have utilised a dual filing strategy to secure patent rights, but...
Read More
GREATER CHINA
How divisional patent applications work in China
Chinese divisional practice is known for its unique timing requirements, prerequisites for filing a divisional, and strict procedural deadlines. For patent holders looking to secure their rights in China,...
Chinese divisional practice is known for its unique timing requirements, prerequisites for filing a divisional, and strict procedural deadlines....
Read More
GREATER CHINA
China | Establishing Inventive Step in Swiss-Type Use Claims – A Case Study on Disease Subtypes and Known APIs
As pharmaceutical innovation increasingly targets specific disease subtypes and personalised therapies, patent protection strategies must evolve accordingly—especially in jurisdictions like China, where method of treatment claims are not patentable. This...
As pharmaceutical innovation increasingly targets specific disease subtypes and personalised therapies, patent protection strategies must evolve accordingly—especially in jurisdictions...
Read More
GREATER CHINA
China | Good faith principle for patent applications
The principle of ‘good faith’ plays a crucial role in ensuring the integrity and reliability of patent applications. This principle is particularly emphasised in China's patent law, where adherence...
The principle of ‘good faith’ plays a crucial role in ensuring the integrity and reliability of patent applications. This...
Read More
GREATER CHINA
China | Recent updates on post-filing data for patent applications
In China's patent examination practice, the technical effects demonstrated by experimental data are a crucial factor for patent applications, especially for biotech and chemical inventions. In order to address objections...
In China's patent examination practice, the technical effects demonstrated by experimental data are a crucial factor for patent applications,...
Read More

Find Your Expert

Experts

Contact Us

Enquiries

Receive Insights

Subscribe